HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- COVID-19 outcomes more severe among individuals with cancer Mark Leiser
-
- It’s a puzzlement Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Patients with cancer, survivors report high rates of alcohol use Jennifer Byrne
- Gabapentin shows efficacy as opioid alternative for patients with head and neck cancer Jennifer Byrne
- NCI pivots some research activities to COVID-19 amid ‘unprecedented disruption’ Mark Leiser
- Mortality unexpectedly high among people with lung cancer, COVID-19 Mark Leiser
- Novel immuno-oncology combination demonstrates activity in metastatic triple-negative breast cancer Mark Leiser
- Multicancer blood test feasible for routine clinical care, could guide intervention John DeRosier
- Talazoparib fails to extend OS vs. chemotherapy in BRCA-mutated advanced breast cancer Mark Leiser
-
- ESR1 mutations predict survival, endocrine therapy failure in early breast cancer Mark Leiser
- Capmatinib shows efficacy in lung cancer subset, including patients with brain metastases Drew Amorosi
- Atezolizumab combination extends PFS in BRAF V600-mutant advanced melanoma John DeRosier
- Geptanolimab shows efficacy in relapsed/refractory peripheral T-cell lymphoma Jennifer R. Southall
- Higher total body irradiation dose fails to improve transplant outcomes in non-Hodgkin lymphoma Mark Leiser
- Individualized anti-thymocyte globulin dosing improves immune reconstitution after HSCT John DeRosier
- Researchers identify factors linked to impaired hematopoietic recovery after CAR T-cell therapy John DeRosier
- CPX-351 prolongs OS compared with 7 + 3 chemotherapy in AML with myelodysplasia-related changes John DeRosier
-
- New VTE incidence ‘significant’ after CAR T-cell therapy for lymphoma Mark Leiser
- Autologous, allogeneic HSCT ‘highly efficacious’ for Waldenström macroglobulinemia Mark Leiser
- Older allogeneic HSCT recipients receive as many potentially inappropriate medications as younger counterparts John DeRosier
- ASCO: ‘Substantial discordance’ in financial disclosures highlights need for ‘harmonized’ approach Jennifer R. Southall
- Less-intensive treatment regimen effective for certain children with B-cell ALL John DeRosier
- High BMI linked to longer survival with immunotherapy for non-small cell lung cancer John DeRosier
- CT scans linked to higher risk for certain cancers Jennifer R. Southall
- Pembrolizumab improves PFS in advanced classical Hodgkin lymphoma
-
- Phase 3 trial evaluating two bladder cancer regimens fails to meet key endpoints
- Tislelizumab-chemotherapy combination extends PFS in non-small cell lung cancer
- Trial of three-agent combination for multiple myeloma misses endpoint
- FDA grants breakthrough therapy status to two cancer therapies
- FDA approves oncology, hematology therapies
- Two regimens receive priority review
- FDA grants fast track designation to BLZ-100 for pediatric central nervous system tumors
- FDA approves additional recommended dosage for Keytruda
-
- American Cancer Society awards research, training grants
- Cancer hospital appoints director of benign hematology
- ASCO awards recognize outstanding contributions to cancer care
- AACR announces president-elect
- City of Hope leaders receive honors